R&D News | pharmaphorum

News

BMS extends its position in ADCs with $180m Orum deal

Bristol-Myers Squibb has signed another deal to build its capabilities in antibody-drug conjugates for cancer, paying $100 million upfront to take control of an Orum Thera

News

EFPIA warns EU reforms will hamstring pharma R&D

A trade organisation representing European pharmaceutical companies warned today that the European Commission’s proposed reforms to pharma legislation could result in the

News

Bayer doubles down on Factor XIa with new phase 3 trial

Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixe

News

Drug combos from AZ, Boehringer show promise in CKD

Combination regimens based on SGLT2 inhibitors and two drugs with different mechanisms of action have shown activity in patients with chronic kidney disease (CKD), raising

News

Innoviva’s ‘game changer’ antibiotic tackles gonorrhoea

Innoviva has moved a step closer to bringing the first novel antibiotic to market for gonorrhoea in decades after reporting positive results in a phase 3 trial.

News

Kronos sheds staff despite positive data for cancer drug

A positive clinical trial is usually a signal for a biotech startup to press the accelerator on its spending, but Kronos Bio is taking a different tack.

BMS extends its position in ADCs with $180m Orum deal

EFPIA warns EU reforms will hamstring pharma R&D

Bayer doubles down on Factor XIa with new phase 3 trial

Drug combos from AZ, Boehringer show promise in CKD

Innoviva’s ‘game changer’ antibiotic tackles gonorrhoea

Kronos sheds staff despite positive data for cancer drug

FDA grants three priority vouchers to psychedelics

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks